lesinurad (DSC)

Drug Overview

Living with gout can mean facing sudden, agonizing attacks of joint pain that disrupt every aspect of daily life. For patients struggling to control this severe form of inflammatory arthritis, the field of Rheumatology offers specialized interventions. This guide provides an in-depth look at lesinurad, an important medication classified within the Uric Acid Transporter Inhibitor drug class, lesinurad (DSC).

Lesinurad is a highly specific Targeted Therapy designed for patients whose gout cannot be controlled by standard medications alone. It is important to note that lesinurad carries a “DSC” (Discontinued) status in certain markets, including the United States, primarily for corporate and manufacturing reasons rather than immediate safety recalls, though its unique kidney-related risk profile requires careful clinical consideration.

• Generic Name: lesinurad
• US Brand Names: Zurampic (DSC)
• Route of Administration: Oral tablet
• FDA Approval Status: FDA-approved (Currently discontinued by the manufacturer in the US market).

What Is It and How Does It Work? (Mechanism of Action)

Gout is a systemic condition driven by hyperuricemia, which is an abnormally high level of uric acid in the blood. When uric acid levels remain high, the compound crystallizes and deposits into joints, triggering massive, painful inflammatory attacks.

Lesinurad is an oral Small Molecule medication that functions as a selective Uric Acid Transporter 1 (URAT1) inhibitor. To understand how it works, we must look at the kidneys. Normally, the kidneys filter uric acid out of the blood, but proteins in the kidney tubules—specifically URAT1 and OAT4—act like molecular vacuums, reabsorbing much of that uric acid back into the bloodstream.

By binding to and blocking these URAT1 and OAT4 transporter proteins, lesinurad stops the kidneys from reabsorbing uric acid. As a result, the body flushes the excess uric acid out through the urine. This is known as a uricosuric effect. By effectively lowering the total uric acid burden in the bloodstream, lesinurad stops new crystals from forming and allows existing joint deposits to dissolve over time.

FDA-Approved Clinical Indications

Primary Indication: Lesinurad is specifically indicated for the treatment of hyperuricemia associated with gout in patients who have not achieved target serum uric acid levels with a xanthine oxidase inhibitor (XOI) alone.

Other Approved & Off-Label Uses:

Because of its highly specific mechanism of action targeting kidney transporters, lesinurad is exclusively utilized for gout. It is not used for other rheumatological conditions like Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, or Systemic Lupus Erythematosus (SLE).

Primary Rheumatology Indications:

In the management of refractory gout, this medication is utilized to achieve the following clinical goals:

• Significantly lower serum uric acid levels to below the target threshold of 6.0 mg/dL (or below 5.0 mg/dL for severe cases).
• Promote the dissolution of tophi (hard, visible deposits of uric acid crystals under the skin and inside joints).
• Prevent future acute gout flares and completely halt the structural joint damage and bone erosion caused by chronic crystal deposition.

Dosage and Administration Protocols

Because lesinurad causes the kidneys to process large amounts of uric acid, it MUST be administered alongside a xanthine oxidase inhibitor (such as allopurinol or febuxostat) to prevent severe kidney complications.

Dose Adjustments and Considerations:

Lesinurad is taken entirely in combination with an XOI; it should never be taken as a standalone therapy (monotherapy). It should be taken at the exact same time as the morning dose of the XOI. Kidney function is critical: lesinurad is contraindicated in patients with severe renal impairment (eGFR less than 30 mL/min), end-stage renal disease, or those on dialysis. It is also not recommended for patients with an eGFR below 45 mL/min.

Dosage must be individualized by a qualified healthcare professional.

Clinical Efficacy and Research Results

Despite its discontinued status in the US, contemporary retrospective analyses and systemic reviews (2020-2026) regarding combination gout therapies consistently reference lesinurad’s clinical trial data to demonstrate the efficacy of dual-mechanism treatment.

During the pivotal Phase 3 CLEAR clinical trials, lesinurad demonstrated significant success in patients who were failing standard therapy. Research showed that adding 200 mg of lesinurad to allopurinol helped approximately 54% to 55% of patients achieve the strict serum uric acid target of less than 6.0 mg/dL by month six, compared to only 28% of patients taking allopurinol alone.

Furthermore, long-term extension data confirmed that maintaining this dual Targeted Therapy effectively reduces the frequency of acute gout flares over a 12-to-24-month period. By keeping uric acid levels suppressed, the medication facilitates the slow but steady reduction of total tophus area, actively slowing structural damage to the joints and preserving patient mobility.

Disclaimer: The research discussed regarding next-generation selective URAT1 inhibitors, the systemic impact of hyperuricemia on chronic kidney disease, and the pathways connecting gout to cardiovascular risk is currently in the preclinical or early investigational phase and is not yet applicable to practical or professional clinical scenarios. 

Safety Profile and Side Effects

BLACK BOX WARNING: Lesinurad carries a severe Black Box Warning regarding the risk of Acute Renal Failure. This medication significantly increases the risk of acute kidney injury when used without a xanthine oxidase inhibitor (XOI). It must strictly be taken in combination with an XOI, and never as monotherapy.

Common Side Effects (>10%):

• Headache
• Influenza-like symptoms
• Increased blood creatinine (a marker of kidney stress)
• Gastroesophageal reflux disease (GERD)

Serious Adverse Events:

• Acute renal failure and kidney stones
• Major Adverse Cardiovascular Events (MACE), including non-fatal myocardial infarction and stroke (though a direct causal link has been widely debated in recent literature).
• Severe hypersensitivity reactions

Management Strategies:

Rigorous laboratory monitoring is required. Doctors must assess renal function (serum creatinine) before initiating therapy and periodically thereafter. Patients must stay highly hydrated, drinking at least 2 liters of water daily to flush the kidneys and prevent uric acid crystal formation in the urinary tract.

Research Areas

In recent rheumatological research spanning 2020 to 2026, the legacy of lesinurad has heavily influenced the development of next-generation therapies. Because of the renal risks associated with first-generation URAT1 inhibitors, current active clinical trials are focusing on newer, highly selective Small Molecule uricosurics (such as dotinurad) that aim to provide the same powerful uric acid-lowering benefits without the associated kidney toxicity.

Additionally, generalized research in the rheumatology space is increasingly focused on the systemic impact of hyperuricemia. Scientists are investigating how chronic uric acid elevation contributes not just to joint destruction, but to severe disease and systemic involvement, including chronic kidney disease progression and cardiovascular inflammation. Understanding how medications like lesinurad clear uric acid helps researchers map the pathways connecting gout to cardiovascular risk.

Patient Management and Clinical Protocols

Pre-treatment Assessment

• Baseline Diagnostics: Joint X-rays or ultrasound to document the presence of erosions and tophi. Baseline pain scores are recorded to measure treatment success over time.
• Organ Function: A comprehensive metabolic panel is absolutely critical to establish a baseline estimated glomerular filtration rate (eGFR) and serum creatinine, ensuring the kidneys can handle the medication.
• Specialized Testing: Baseline serum uric acid levels must be documented.
• Screening: Cardiovascular risk assessment and a review of any history of kidney stones.

Monitoring and Precautions

• Vigilance: Doctors will monitor your serum uric acid levels every 2 to 4 weeks during the early stages of treatment to ensure the medication is working. Kidney function (creatinine) must be checked frequently. Note that gout “flares” may temporarily increase when starting any uric acid-lowering therapy as crystals begin to shift and dissolve; doctors often prescribe a low-dose anti-inflammatory for the first few months to manage this.
• Lifestyle: Maintaining a high fluid intake is mandatory. Patients should adopt a low-purine diet (limiting red meat, shellfish, and high-fructose corn syrup) and focus on gentle joint protection techniques during active flares.
• Do’s and Don’ts
  • DO take this medication at the exact same time as your allopurinol or febuxostat, preferably in the morning with food and a full glass of water.
  • DO drink at least 2 liters (about 8 glasses) of water every single day.
  • DON’T stop taking your medication during a gout flare unless explicitly instructed by your doctor; stopping can make the flare last longer.
  • DON’T ever take lesinurad alone without your other primary gout medication.

Legal Disclaimer

The information provided in this article is for educational and informational purposes only and does not constitute medical advice. Treatment plans, dosages, and medication choices must be individualized by a qualified healthcare professional. Always consult your physician or specialist rheumatologist before starting, stopping, or altering any medical treatment.